This report is based on the findings from two focused After-Action reviews (AARs) in Norway and Georgia that discussed the use of evidence in the advice-making process for long-term care facilities (LTCFs) during the start of the COVID-19 Omicron wave in early 2022.
ECDC welcomes the authorisation of the first vaccine against COVID-19 in EU/EEA. We have been looking forward to this moment for a long time.
On 21 December, EMA recommended granting a conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 (COVID-19) in people from 16 years of age. On the same day, the European Commission has granted market authorisation for EU-wide use.
The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) are recommending that second booster doses of COVID-19 vaccines be considered for people between 60 and 79 years old and people with medical conditions putting them at high risk of severe disease.
This pilot protocol is primarily intended to guide the implementation of a first pilot ECDC-funded study using routinely collected data, and includes a concise overview of the systems of the countries included in the pilot study.
COVID-19 is a highly infectious disease caused by the most recently discovered coronavirus. Everyone is responsible for reducing the spread by taking these simple precautions. Together we can protect ourselves and all those around us.
The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, focusing in particular on the experience in EU/EEA countries since the beginning of the pandemic. This document also addresses transmission to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing, and the effectiveness and impacts of school closures.
ECDC is creating new infrastructure to allow for regular monitoring and analysis of COVID-19 vaccine effectiveness (VE) over time, using a multi-country approach, through the implementation of studies in different settings.